Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation - Lamon-Fava, Stefania; So, Jisun; Mischoulon, David; Ziegler, Thomas R.; Dunlop, Boadie W.; Kinkead, Becky; Schettler, Pamela J.; Nierenberg, Andrew A.; Felger, Jennifer C.; Maddipati, Krishna Rao; Fava, Maurizio; Rapaport, Mark Hyman (Prostaglandins, leukotrienes and essential fatty acids, 2021)
Keywords: Adult; Aged; arachidonic acid; blood serum; Body Mass Index; C-reactive protein; Chronic Disease; Depressive Disorder, Major - blood; Depressive Disorder, Major - drug therapy; dose response; Dose-Response Relationship, Drug; eicosapentaenoic acid; Eicosapentaenoic acid (EPA); Eicosapentaenoic Acid - administration & dosage; Eicosapentaenoic Acid - pharmacokinetics; Female; Humans; inflammation; Inflammation - blood; Inflammation - drug therapy; leukotrienes; liquid chromatography; major depressive disorder (MDD); Male; mass spectrometry; mental depression; metabolites; Middle Aged; Omega-3 fatty acids; placebos; Pro-resolving lipid mediators (SPM); prostaglandins; Omega-3 fatty acids; major depressive disorder (MDD); Eicosapentaenoic acid (EPA); Pro-resolving lipid mediators (SPM)